Optimal glycemic target level for colon cancer patients with diabetes

Abstract

A optimal glycemic control level for colon cancer patients with diabetes should be recommended as an HbA1c of 7.8% or below.

The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies

“…By reading the full text, 101 studies were excluded for different reasons, and 5 studies did not provide sufficient data to calculate the outcome effect estimates. Finally, 36 studies were included in our meta-analysis[6–20, 27–47]. The study selection process for inclusion in our meta-analysis was shown in Fig 1.…”

“…In our meta-analysis, year of publication ranged from 2003 to 2016, and the regions included 2 American countries[7, 13–15, 18, 19, 27, 30, 33, 37, 41, 42, 45, 46], 6 European countries[6, 11, 17, 28, 32, 39, 40, 44], 2 Asian countries[8, 9, 12, 16, 20, 29, 34–36, 38, 43, 47] and 1 Oceania country[31]; the included studies contained 15 retrospective[9, 10, 14, 16–20, 27, 33, 36, 37, 39, 41, 47] and 21 prospective[6–8, 11–13, 15, 28–32, 34, 35, 38, 40, 42–46] cohort studies; the sample size ranged from 391 to 1056243, and the mean age of study ranged from 46.4 to 72.07. In DM ascertainment, 25 studies[6, 8, 9, 11–15, 18, 19, …”

“…In DM ascertainment, 25 studies[6, 8, 9, 11–15, 18, 19, 28, 29, 31, 33–37, 39–42, 44–46] used the method of medical records, 5 studies[16, 20, 38, 43, 47] used the method of blood sugar test, and 6 studies[7, 10, 17, 27, 30, 32] used the method of self-reported. To avoid the effects of confounders, we preferred to extract the adjusted outcome effect estimates, but we still found that the outcome effect estimates of 4 studies were not adjusted.…”

“…The number of studies on the colon cancer data provided was 18[6, 8, 10–13, 28, 31, 40, 41, 44–47]. There was only one study on CVDS, and the pooled HR on CVDS was not analyzed.…”

Importance of glycemic control in cancer patients with diabetes: Treatment through end of life

“…[ 18 ] This lack of attention to their diabetes can affect their glycemic status and increase their risk for hospitalizations and increased symptom severity and may shorten their lives. [ 11 28 29 30 31 ] Adults with cancer and diabetes have a higher prevalence of nonadherence to their oral antidiabetic agents than adults with diabetes who do not have cancer, and this nonadherence increases the risk for poor glycemic control. Adherence to oral agents is associated with 24% fewer hospitalizations in cancer patients with diabetes.…”